Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Kentucky: - Baptist Health Hardin — Elizabethtown, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
- The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in Kentucky: - Research Site — Lexington, Kentucky
- Research Site — Louisville, Kentucky
Phase 3 Recruiting Industry
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
Sponsor: Amgen
NCT ID: NCT06691984
Sites in Kentucky: - University of Louisville Health - James Graham Brown Cancer Center — Louisville, Kentucky
- Norton Cancer Institute — Louisville, Kentucky
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
- University of Kentucky/Markey Cancer Center — Lexington, Kentucky
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Kentucky: - Research Site 115 — Louisville, Kentucky
Phase 2 Recruiting Industry
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…
Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Kentucky: - St. Elizabeth Healthcare — Edgewood, Kentucky
- University Medical Center, lnc.:DBA University of Louisville Hospital — Louisville, Kentucky
- University of Louisville — Louisville, Kentucky
- UofL Health Brown Cancer Center — Louisville, Kentucky
Phase 2 Recruiting Federal
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…
Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Kentucky: - Robley Rex VA Medical Center, Louisville, KY — Louisville, Kentucky
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Kentucky: - Exelixis Clinical Site #122 — Louisville, Kentucky
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Kentucky: - Norton Cancer Institute Pharmacy, Downtown Pharmacy — Louisville, Kentucky
- Norton Cancer Institute Pharmacy — Louisville, Kentucky
- Norton Cancer Institute, Norton Healthcare Pavilion — Louisville, Kentucky
- Norton Hospital — Louisville, Kentucky
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Elizabeth Healthcare Edgewood — Edgewood, Kentucky
- Saint Elizabeth Healthcare Fort Thomas — Fort Thomas, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky